HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy.

AbstractBACKGROUND:
Outcomes after thoracic metastasectomy in patients with testicular germ cell tumors (GCTs) who received first-line chemotherapy alone versus salvage chemotherapy remain unexplored.
METHODS:
We conducted a retrospective review of patients who underwent thoracic metastasectomy for residual GCT between 1997 and 2019 at a single tertiary center. Factors associated with progression-free survival (PFS) and overall survival (OS) were assessed using multivariable Cox regression.
RESULTS:
Of 251 patients, 191 received only first-line chemotherapy (76%) and 60 received salvage chemotherapy (24%). Median follow-up was 3.45 years (interquartile range, 1-7.93 years). Among first-line patients without teratoma in the primary tumor, with necrosis in the retroperitoneal nodes and normalized or decreasing serum tumor markers, 17 of 20 had intrathoracic necrosis (85%). Among first-line and salvage patients, respectively, 5-year OS was 93% (95% confidence interval [CI], 89%-98%) versus 63% (95% CI, 51%-78%; P < .001), and 5-year PFS was 69% (95% CI, 62%-77%) versus 40% (95% CI, 29%-56%; P < .001). On multivariable analysis, multiple lung lesions (hazard ratio [HR] = 3.01; 95% CI, 1.50-6.05; P = .002) and brain metastasis (HR = 4.51; 95% CI, 2.34-8.73; P < .001) at diagnosis, salvage chemotherapy (HR = 1.85; 95% CI, 1.10-3.13; P = .021), teratoma (HR = 2.68; 95% CI, 1.50-4.78; P = .001), and viable malignancy (HR = 4.34; 95% CI, 2.44-7.71; P < .001) were associated with worse PFS.
CONCLUSIONS:
Although GCT patients treated with salvage chemotherapy followed by thoracic metastasectomy have more aggressive disease and poorer PFS, they can achieve encouraging OS. Our findings highlight the integral role of aggressive thoracic metastasectomy in the treatment of GCT patients with residual thoracic disease after first line-only or salvage chemotherapy.
AuthorsRaul Caso, Gregory D Jones, Kay See Tan, George J Bosl, Samuel A Funt, Joel Sheinfeld, Victor E Reuter, David Amar, Gregory Fischer, Daniela Molena, Gaetano Rocco, Manjit S Bains, Darren R Feldman, David R Jones
JournalThe Annals of thoracic surgery (Ann Thorac Surg) Vol. 111 Issue 4 Pg. 1141-1149 (04 2021) ISSN: 1552-6259 [Electronic] Netherlands
PMID32882201 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Topics
  • Adult
  • Disease-Free Survival
  • Humans
  • Lymph Nodes (pathology)
  • Male
  • Metastasectomy (methods)
  • Neoplasm Metastasis
  • Neoplasm Staging (methods)
  • Neoplasms, Germ Cell and Embryonal (diagnosis, secondary, therapy)
  • Prognosis
  • Retrospective Studies
  • Salvage Therapy (methods)
  • Testicular Neoplasms (diagnosis, secondary, therapy)
  • Thoracic Surgical Procedures (methods)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: